证券之星消息，截至2026年1月23日收盘，可孚医疗(301087)报收于56.45元，上涨2.28%，换手率 1.69%，成交量3.29万手，成交额1.85亿元。 1月23日的资金流向数据方面，主力资金净流入861.71万元，占总成交额4.65%，游资资金净流入764.55 万元，占总成交额4.13%，散户资金净流出1626.25万元，占总成交额8.78%。 该股主要指标及行业内排名如下： 可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗器械的研发、生产、销售和服务。 该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家；过去90天内机构目标 ...

Group 1 - The company, David Medical, reported that as of January 20, 2026, the total number of shareholders is approximately 19,700 [1]

Group 1 - The core point of the article is that Opcon Vision (300595) reported a total of 63,118 shareholders as of January 20, 2026 [1]

Core Viewpoint - The company, Opcon Vision, has no plans to change its name, emphasizing the brand's long-standing presence and trust within the industry and among consumers [1] Brand Value - The name "Opcon Vision" has been associated with the company's development for many years, contributing to a strong brand reputation and market recognition [1] Trust and Stability - The company highlights the importance of brand heritage, the stability of its existing trademark system, and the compatibility of its full industry chain business layout in its decision to maintain the current name [1]

Group 1 - The company announced the convening of its fourth board meeting on January 23, 2026, to review the proposal for repurchasing unvested shares from the second employee stock ownership plan [1] - The company plans to repurchase a total of 1,829,868 shares of its stock that are not eligible for unlocking under the second employee stock ownership plan [1]

Core Viewpoint - The company, Furu Medical (300049.SZ), projects a net profit attributable to shareholders of 135 million to 164 million yuan for 2025, reflecting a year-on-year change of 19.17% to 44.77% [1] Group 1: Financial Projections - For 2025, the medical device business of the French subsidiary is expected to achieve revenue of approximately 1.05 billion to 1.2 billion yuan, with a year-on-year growth of about 13.77% to 30.02% [1] - The net profit from the medical device business is projected to be around 220 million to 260 million yuan, representing a year-on-year increase of approximately 15.48% to 36.47% [1] - The net profit attributable to shareholders from the medical device business is estimated to be about 110 million to 130 million yuan, showing a year-on-year growth of approximately 15.27% to 36.23% [1] Group 2: Other Business Segments - The company plans to adhere to a managed care strategy, with revenue from pharmaceuticals, medical services, and other businesses expected to be around 450 million to 480 million yuan, leading to a net profit attributable to shareholders of approximately 25 million to 34 million yuan [1] - The impact of non-recurring gains and losses on net profit is anticipated to be in the range of -2 million to -8 million yuan for 2025 [1]

Group 1 - The core viewpoint of the article is that Aibo Medical has confirmed normal management of accounts receivable and no equity pledge risk for its major shareholder [1] Group 2 - As of the current date, the company states that its accounts receivable management is functioning normally [1] - The major shareholder of the company has no equity pledge situation [1] - There is no existence of pledge risk associated with the company's major shareholder [1]

Core Viewpoint - Dabo Medical (002901) shows strong financial performance with significant year-on-year growth in revenue and net profit, indicating a positive outlook for the company in the medical high-value consumables sector [2]. Financial Performance - For the first three quarters of 2025, Dabo Medical reported a main revenue of 1.876 billion yuan, an increase of 22.69% year-on-year [2]. - The net profit attributable to shareholders reached 425 million yuan, reflecting a substantial growth of 77.03% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 346 million yuan, up by 63.99% year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 666 million yuan, a year-on-year increase of 17.82% [2]. - The single-quarter net profit attributable to shareholders was 180 million yuan, marking a 77.49% increase year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was 123 million yuan, up by 38.44% year-on-year [2]. - The company's debt ratio stands at 24.53%, with investment income of 5.81 million yuan and financial expenses of -23.87 million yuan [2]. - The gross profit margin is reported at 71.23% [2]. Market Activity - As of January 23, 2026, Dabo Medical's stock closed at 50.15 yuan, with an increase of 1.48% [1]. - The trading volume was 20,400 hands, with a total transaction amount of 102 million yuan [1]. - The net outflow of main funds was 1.6977 million yuan, accounting for 1.67% of the total transaction amount, while retail investors saw a net inflow of 6.51 million yuan, representing 6.4% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, one institution has given a buy rating for Dabo Medical [3].

Core Insights - The main viewpoint of the article highlights the limitations of traditional mental health diagnostic methods and introduces a non-invasive brain-computer interface technology as a more efficient and objective solution for diagnosing conditions like depression and anxiety [1] Group 1: Current Diagnostic Methods - Current mainstream methods for diagnosing mental health issues rely on a combination of "scale assessment + comprehensive judgment by doctors," which is time-consuming and difficult to quantify [1] - In non-hospital settings, such as community screenings or corporate health management, the lack of professional psychological resources can lead to subjective biases in results [1] Group 2: Innovative Solutions - The non-invasive brain-computer interface technology offers a solution by utilizing real-time EEG signal collection and AI analysis for efficient and objective assessments [1] - The core competitive advantage of Haoshi Tianhui lies in its fully self-developed non-invasive brain-computer interface technology system, which includes high-precision AI algorithms that decode EEG signals into quantifiable emotional indicators [1] Group 3: Product Features and Efficacy - The developed system can conduct tests for depression and anxiety in as little as 90 seconds per session, achieving an accuracy rate of over 90% [1] - The system has received medical device registration certification and integrates a software platform that generates customized therapeutic music based on real-time EEG data, creating a complete "assessment-intervention-feedback" loop [1] Group 4: Market Potential and Expansion - The solution significantly reduces subjective bias and enhances screening efficiency, making it applicable in various settings such as hospitals, education, and justice [1] - Recent policy support in China for mental health diagnosis, including the incorporation of AI+EEG diagnostics into national medical guidelines, creates favorable commercialization conditions [1] - Haoshi Tianhui has initiated collaborations with medical institutions and distributors in regions like Yunnan, Guizhou, Sichuan, Jiangxi, Guangdong, Hebei, and Jiangsu-Zhejiang-Shanghai to accelerate product scaling [1] - Future plans include expanding into consumer applications through the sale of devices and consumables, as well as a system service model to achieve sustainable revenue growth [1]

Core Viewpoint - The brain-computer interface (BCI) industry is identified as a long-term investment opportunity in the healthcare sector, with significant strategic importance for the company in the medical device field [1] Summary by Relevant Sections Industry Outlook - The implementation opinions jointly issued by seven departments, including the Ministry of Industry and Information Technology, aim to establish an advanced technology, industry, and standard system for the BCI industry by 2027, and to cultivate 2 to 3 globally influential leading enterprises by 2030 [1] Company Strategy - The company has been researching and exploring the BCI direction since 2023 and strategically invested in Hangzhou Qingshi Yongjun in 2025, successfully entering the invasive BCI treatment field for severe treatment-resistant depression [1] - The recent investment in Haoshi Tianhui further enhances the company's detection and treatment layout for depression and anxiety disorders within the BCI field [1] Future Plans - The company plans to continue its strategic layout in the BCI field by participating deeply through its investment platform, using its own funds for equity participation or acquisitions to accelerate the product industrialization and commercialization processes of invested enterprises [1] - Additionally, the company intends to establish a BCI industry fund, leveraging the strengths and resources of professional investment institutions to expedite its industrial chain layout in the BCI and neuroscience fields [1]